DsbA-L: A Promising Therapeutic Target for Metabolic Diseases

Ming Yang; Shilu Luo; Jinfei Yang; Wei Chen; Liyu He; Di Liu; Xi Wang; Li Xiao; Lin Sun

doi:10.2174/0109298673252630231018044159

DsbA-L: A Promising Therapeutic Target for Metabolic Diseases

Curr Med Chem. 2023 Oct 24. doi: 10.2174/0109298673252630231018044159. Online ahead of print.

Authors

Ming Yang¹, Shilu Luo¹, Jinfei Yang¹, Wei Chen¹, Liyu He¹, Di Liu¹, Xi Wang², Li Xiao¹, Lin Sun¹

Affiliations

¹ Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, China; Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China.
² Department of Nutrition, Xiangya Hospital, Central South University, Changsha, Hunan, China.

PMID: 37877503
DOI: 10.2174/0109298673252630231018044159

Abstract

The increasing incidence of metabolic diseases, including obesity and diabetes, is a serious social public problem. Therefore, there is an urgent need to find effective prevention and treatment measures for these diseases. DsbA-L is a protein that is widely expressed in many tissues and is closely related to metabolism. Emerging evidence shows that DsbA-L plays an important role in antioxidative stress, promoting the synthesis and secretion of adiponectin and maintaining mitochondrial homeostasis, and the abnormalities of these functions are also closely related to the occurrence and development of metabolic diseases. Here, we reviewed the tissue expression patterns and regulatory factors of DsbA-L, summarized its biological functions and the current research progress of DsbA-L in metabolic diseases, and found that DsbA-L may be a promising target for metabolic diseases.

Keywords: DsbA-L; antioxidative stress; diabetes; kidney; metabolic diseases; obesity.